Winkler, André Berger, Markus Ehlers, Marc MALDI-TOF MS glycan analysis of RhD-specific IgG antibodies (crude data) <p>Series_A_09037-013_total_IgG.csv<br>MALDI-TOF MS glycan analysis of total IgG from Rhophylac, which was the starting material for the purification of Rhesus D (RhD)-specific IgG antibodies (purification A). The area under the peak is shown for each selected molecular mass (m/z) and presented as percentage of all the indicated area values. The glycan structure and abbreviation for each m/z is shown in Supplementary Figure 2 and the summary of all MALDI-TOF MS analyses is shown in Figure 1 in the main text.</p> <p>Series_A_09037-012_RhD-specific_IgG.csv<br>MALDI-TOF MS glycan analysis of RhD-specific IgG antibodies (purification A). The area under the peak is shown for each selected molecular mass (m/z) and presented as percentage of all the indicated area values. The glycan structure and abbreviation for each m/z is shown in Supplementary Figure 2 and the summary of all MALDI-TOF MS analyses is shown in Figure 1 in the main text.</p> <p>SeriesB_09037-192a total_IgG.csv<br>MALDI-TOF MS glycan analysis (measurement a of a duplicate measurement) of total IgG from Rhophylac, which was the starting material for the purification of RhD-specific IgG antibodies (purification B). The area under the peak is shown for each selected molecular mass (m/z) and presented as percentage of all the indicated area values. The glycan structure and abbreviation for each m/z is shown in Supplementary Figure 2 and the summary of all MALDI-TOF MS analyses is shown in Figure 1 in the main text.</p> <p>SeriesB_09037-192b total_IgG.csv<br>MALDI-TOF MS glycan analysis (measurement b of a duplicate measurement) of total IgG from Rhophylac, which was the starting material for the purification of RhD-specific IgG antibodies (purification B). The area under the peak is shown for each selected molecular mass (m/z) and presented as percentage of all the indicated area values. The glycan structure and abbreviation for each m/z is shown in Supplementary Figure 2 and the summary of all MALDI-TOF MS analyses is shown in Figure 1 in the main text.</p> <p>Series_B_09037-191a_RhD-specific_IgG.csv<br>MALDI-TOF MS glycan analysis (measurement a of a duplicate measurement) of RhD-specific IgG antibodies (purification B). The area under the peak is shown for each selected molecular mass (m/z) and presented as percentage of all the indicated area values. The glycan structure and abbreviation for each m/z is shown in Supplementary Figure 2 and the summary of all MALDI-TOF MS analyses is shown in Figure 1 in the main text.</p> <p>SeriesB_09037-191b RhD-specific_IgG .csv<br>MALDI-TOF MS glycan analysis (measurement b of a duplicate measurement) of RhD-specific IgG antibodies (purification B). The area under the peak is shown for each selected molecular mass (m/z) and presented as percentage of all the indicated area values. The glycan structure and abbreviation for each m/z is shown in Supplementary Figure 2 and the summary of all MALDI-TOF MS analyses is shown in Figure 1 in the main text.</p> <p> </p> igg;glycan;endos;flow cytometry;immunoglobulin;antibody;red blood cells;Rhesus D prophylaxis;prenancy;sialyation;Medicine;Molecular Biology 2013-08-12
    https://f1000.figshare.com/articles/dataset/MALDI_TOF_MS_glycan_analysis_of_RhD_specific_IgG_antibodies_crude_data_/761185
10.6084/m9.figshare.761185.v1